A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer

LESSONS LEARNED: The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily. The limited anticancer activity observed in this unselected patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kim, Richard, Tan, Elaine, Wang, Emily, Mahipal, Amit, Chen, Dung‐Tsa, Cao, Biwei, Masawi, Fadzai, Machado, Cindy, Yu, James, Kim, Dae Won
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186409/
https://ncbi.nlm.nih.gov/pubmed/32776632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados